ZS Oncology Watchdog Report: Indication-Based Pricing

Christina Corridon

> Download

Currently, oncology drugs have the same price across indications, and payers reimburse the same amount across them. However, in the quest to achieve more value-based approaches to pricing, U.S. healthcare companies are beginning to experiment with indication-based pricing methodologies. In these methodologies, the price of a drug differs across indications in accordance with the benefits the drug provides. This report describes how drug companies can use indication-specific differential pricing to bring the cost of treatment into better alignment with clinical benefits.

About the Expert

Christina Corridon is a Manager in the Boston office and a leader in the ZS Oncology Practice. She has over a decade experience working in the pharmaceutical and biotech industries, with specific expertise in oncology and biosimilars. During her consulting career she has worked on US and global projects spanning commercialization strategy including launch strategy and planning, go-to market strategy, commercial models, marketing strategy and brand planning. Christina has an MPH in Health Policy and Management from the UCLA Fielding School of Public Health and an MBA from the Stern School of Business at New York University focused in Marketing. Christina completed her BA at Cornell University.                 

Contact ZS